RBC Capital Downgrades Alpine Immune Sciences to Sector Perform, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza downgraded Alpine Immune Sciences (ALPN) from Outperform to Sector Perform while raising the price target from $41 to $65.
April 11, 2024 | 10:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alpine Immune Sciences was downgraded by RBC Capital from Outperform to Sector Perform, but the price target was increased from $41 to $65.
The downgrade to Sector Perform suggests a neutral outlook on ALPN's stock performance in the short term, indicating that the stock might perform in line with the market or sector. However, the increase in the price target from $41 to $65 reflects a positive view on the company's valuation or future earnings potential. This mixed signal could lead to short-term uncertainty among investors, balancing the potential for both positive and negative reactions in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100